Ruijin Hospital
上海交通大学医学院附属瑞金医院
Listed for 24 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Ruijin Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led1 open trial led
- Hepatocellular carcinoma肝细胞癌35 papers led3 open trials led
- Stomach cancer胃癌96 papers led13 open trials led
- Osteosarcoma骨肉瘤13 papers led1 open trial led
- Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤22 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病11 papers led4 open trials led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Haemophilia A血友病 A5 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
- Moyamoya disease烟雾病2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led
- Fabry disease法布雷病3 papers led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病4 papers led2 open trials led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Aplastic anaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.
18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06596954
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingRadiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2023-01
- Registry
- NCT05978193
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 1 listed hospital as study siteShanghai
- RecruitingComparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2019-09
- Registry
- NCT04135664
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- The Clinical Value of hsa_circ_0000419 in Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
- Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled
- Sparing lymphocytes during preoperative adjuvant radiotherapy for oesophageal squamous cell carcinoma (SPARE): protocol for an open-label, randomised controlled trial.
- CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
- Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort.
- TROAP promotes esophageal squamous cell carcinoma progression via the PI3K/AKT pathway.
- Radiomics applications in the modern management of esophageal squamous cell carcinoma.
- Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.
- Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).
- Retrospective Analysis of CT-based Habitat Analysis for Predicting pCR and Survival of ESCC Treated by Neoadjuvant Chemoradiotherapy and Esophagectomy.
- The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort.
- Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.
- A novel computational model ITHCS for enhanced prognostic risk stratification in ESCC by correcting for intratumor heterogeneity.
- Real-world evaluation of multimodal treatment practice in older oesophageal cancer patients.
- A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors.
- Robotic Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer: A Meta-analysis.
- High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
- Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
- Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma".
- Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
- Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).
- Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population.
All its trials on ClinicalTrials.gov, any status11
- Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
- Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
- Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus
- Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
- Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)21
- Association of Skeletal Muscle and Adiposity Measured by Computed Tomography with Toxicity and pCR in Esophageal Squamous Cell Carcinoma Receiving Standardized Neoadjuvant Chemoradiotherapy
- The Predictive Value of Pretreatment Peripheral T-Lymphocyte Subsets for Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma Patients Undergoing Neoadjuvant Chemoradiotherapy: A Prospective Cohort Analysis
- Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- First Exploration of the Characterization and Dosimetric Predictors for Absolute Lymphocyte Count Changes during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma: An Analysis of a Prospective Cohort
- 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
- 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- A propensity score–matched analysis to evaluate the benefit of adjuvant therapy on disease progression of esophageal squamous cell carcinoma after R0 esophagectomy.
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).
- P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- Prediction of Response to Neoadjuvant Chemoradiotherapy Combined with Pembrolizumab in Esophageal Squamous Cell Carcinoma with CT/FDG PET Radiomic Signatures Based on Machine Learning Classification
- Sarcopenia as a Predictor of Neoadjuvant Therapy-Related Toxicity in Esophageal Squamous Cell Carcinoma Patients
- Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).
- Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14
- Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial
- Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 35 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.
15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07331883
Age 18 years to 75 years (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- RecruitingThe Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06746194
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingDigitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Phase
- Not given
- Started
- 2023-03
- Registry
- NCT05870969
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led35
- RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1 -mutated hepatocellular carcinoma.
- Radiomics with Machine Learning Improves the Prediction of Microscopic Peritumoral Small Cancer Foci and Early Recurrence in Hepatocellular Carcinoma.
- Suppression of pseudogene MT2P1 transcription induced by E2F7 inhibits hepatocellular carcinoma cell proliferation and facilitates apoptosis via preserving its parental gene.
- Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence.
- Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine.
- Preoperative Multifrequency MR Elastography for Stratifying Wnt/β-Catenin Pathway and Microvascular Invasion Phenotypes in Hepatocellular Carcinoma.
- Paracancerous binuclear hepatocytes assessed by computer program is a novel biomarker for short term recurrence of hepatocellular carcinoma after surgery.
- A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR-II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma.
- Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
- Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1.
- The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.
- FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.
- METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation.
- Three-Dimensional Multifrequency MR Elastography for Microvascular Invasion and Prognosis Assessment in Hepatocellular Carcinoma.
- Risk predictive model for the development of hepatocellular carcinoma before initiating long-term antiviral therapy in patients with chronic hepatitis B virus infection.
- Alternative splicing-related long noncoding RNA ANRIL facilitates hepatocellular carcinoma by targeting the miR-199a-5p/SRSF1 axis and impacting Anillin.
- Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study.
- Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.
- Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.
- Attenuation of binuclear hepatocytes in the paracancerous liver tissue is associated with short-term recurrence of hepatocellular carcinoma post-radical surgery.
- Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
- Editorial for "LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study".
- Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis.
- Circular RNA circ SET domain containing 2 (circSETD2) inhibits hepatocellular carcinoma cell proliferation and invasion in vivo and in vitro.
- Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
- PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.
- E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription.
- Pseudogene SNRPFP1 derived long non-coding RNA facilitates hepatocellular carcinoma progress in vitro by sponging tumor-suppressive miR-126-5p.
- Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma.
- Immunological effect of irreversible electroporation on hepatocellular carcinoma.
- Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach.
- PHF19 activates hedgehog signaling and promotes tumorigenesis in hepatocellular carcinoma.
- ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.
- Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning.
- The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Chinese-language papers (not in the count)3
- [Value of albumin RNAscope in situ hybridization in diagnosis and differential diagnosis of hepatocellular carcinoma].
- [Standardized screening and early imaging diagnosis strategies for hepatocellular carcinoma].
- [Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].
All its trials on ClinicalTrials.gov, any status11
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
- Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients
Cancer
Stomach cancer
胃癌Led 96 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.0%.
18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 23
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07556640
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSystemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06519591
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingIBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07025889
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPerioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07026149
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAdjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07366528
Age 18 years to 80 years (registered criteria)
Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai
- RecruitingPredicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07824479
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07867392
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingThe Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06597526
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPrediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2020-09
- Registry
- NCT05140746
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingNon-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- Phase
- Not given
- Started
- 2026-04
- Registry
- NCT07554742
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingGK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- Phase
- Phase 1
- Started
- 2026-11
- Registry
- NCT07923396
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingFruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06888037
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingDragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- Phase
- Phase 3
- Started
- 2021-09
- Registry
- NCT04384601
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06901531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingDevelopment and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07068529
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDevelopment and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
- Phase
- Not given
- Started
- 2025-06
- Registry
- NCT07076979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06221748
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingApplication of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06679244
Age 18 years to 80 years (registered criteria)
Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai
- RecruitingComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05918094
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
- RecruitingA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Phase
- Phase 1
- Started
- 2022-06
- Registry
- NCT05365581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou
- Not yet recruitingProspective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07746830
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led96
- Super-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer.
- Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.
- Machine Learning-Driven SERS Analysis Platform for Accurate and Rapid Diagnosis of Peritoneal Metastasis from Gastric Cancer.
- Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immuno
- Loss of DRD5P2 in hypoxia attenuates Rock2 degradation to promote EMT and gastric cancer metastasis.
- USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer.
- Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer.
- Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction.
- Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer.
- Predictive value of label-free surface-enhanced Raman spectroscopy for locally advanced gastric cancer following neoadjuvant chemoimmunotherapy.
- Gallstones, cholecystectomy, and cancer risk: an observational and Mendelian randomization study.
- Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.
- Resveratrol targets mitochondrial USP36-SOD2 to induce autophagy-ferroptosis and inhibit gastric cancer progression.
- FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis.
- SIGLEC11 promotes M2 macrophage polarization through AKT-mTOR signaling and facilitates the progression of gastric cancer.
- Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
- Malignant gastric glomus tumor with heterochronous liver metastases: a case report and review of the literature.
- Multi-Omics Analysis Reveals OBSCN as a Key Modulator of Tumor Microenvironment, Microbial Signatures and Clinical Outcomes in Gastric Cancer.
- Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers.
- Overlap Versus π-Shaped Esophagojejunostomy After Laparoscopic Total Gastrectomy for Gastric Cancer: A Comparative Study.
- Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in gastric adenosquamous carcinoma.
- The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer.
- Improving diagnosis and outcome prediction of gastric cancer via multimodal learning using whole slide pathological images and gene expression.
- The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.
- PHF10 inhibits gastric epithelium differentiation and induces gastric cancer carcinogenesis.
- Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids.
- The effect of self-designed metabolic equivalent exercises on cancer-related fatigue in patients with gastric cancer: A randomized controlled trial.
- SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer.
- In-hospital outcomes of older patients with gastric cancer and their risk factors: large comprehensive institution-based study.
- Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10.
- Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.
- Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer.
- Cytotoxic effects of NIR responsive chitosan-polymersome layer coated melatonin-upconversion nanoparticles on HGC27 and AGS gastric cancer cells: Role of the ROS/PI3K/Akt/mTOR signaling pathway.
- Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer.
- GC-CDSS: Personalized gastric cancer treatment recommendations system based on knowledge graph.
- Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
- Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.
- Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.
- Tumor-mesothelium HOXA11-PDGF BB/TGF β1-miR-181a-5p-Egr1 feedforward amplifier circuity propels mesothelial fibrosis and peritoneal metastasis of gastric cancer.
- VPS35 promotes gastric cancer progression through integrin/FAK/SRC signalling-mediated IL-6/STAT3 pathway activation in a YAP-dependent manner.
- Latest guideline of endoscopic submucosal dissection of early gastric cancer may not be suitable for Chinese patients: retrospective study findings from two centers.
- CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients.
- Efficacy and prognostic value of delta radiomics on dual-energy computed tomography for gastric cancer with neoadjuvant chemotherapy: a preliminary study.
- BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.
- Androgen receptor promotes cell stemness via interacting with co-factor YAP1 in gastric cancer.
- The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
- HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer.
- VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer.
- Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer.
- Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.
- Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer.
- Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling.
- A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images.
- Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming.
- Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.
- Intra-abdominal fat volume estimation by multi-detector rows computed tomography: relevance in surgical fellowship training program in Shanghai: a retrospective study.
- Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation.
- Euclidean distance-based Raman spectroscopy (EDRS) for the prognosis analysis of gastric cancer: A solution to tumor heterogeneity.
- CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation.
- Long non-coding RNA NUT family member 2A-antisense RNA 1 sponges microRNA-613 to increase the resistance of gastric cancer cells to matrine through regulating oxidative stress and vascular endothelial growth factor A.
- A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy: Initial Experience Compared with Roux-en-Y Anastomosis.
- Initial screening of gastric cancer using oral contrast-enhanced trans-abdominal ultrasonography in rural asymptomatic individuals.
- LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling.
- CRISPR/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells.
- Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.
- Endoscopic closure of a large gastric mucosal defect after endoscopic submucosal dissection using a novel endoscopic string-with-knotter suture device.
- Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy.
- CHRDL2 promotes cell proliferation by activating the YAP/TAZ signaling pathway in gastric cancer.
- Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.
- Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.
- Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
- A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial.
- Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
- A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
- Atranorin driven by nano materials SPION lead to ferroptosis of gastric cancer stem cells by weakening the mRNA 5-hydroxymethylcytidine modification of the Xc-/GPX4 axis and its expression.
- Application Value of 4K High-Definition System in Laparoscopic Gastrectomy: Preliminary Results and Initial Experience.
- Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.
- The dynamic alteration of transcriptional regulation by crucial TFs during tumorigenesis of gastric cancer.
- Pangenomic analysis of Chinese gastric cancer.
- A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.
- An xception model based on residual attention mechanism for the classification of benign and malignant gastric ulcers.
- Quantifying the cell morphology and predicting biological behavior of signet ring cell carcinoma using deep learning.
- Assessment of liver metastases radiomic feature reproducibility with deep-learning-based semi-automatic segmentation software.
- Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
- A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.
- LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation.
- Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data.
- ATP5B promotes the metastasis and growth of gastric cancer by activating the FAK/AKT/MMP2 pathway.
- A randomized controlled trial to evaluate omentum-preserving gastrectomy for patients with T1-T3 gastric cancer.
- YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis.
- Staged laparoscopic management of locally advanced gastric cancer with outlet obstruction.
- Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.
- The Validity of the GLIM Criteria for Malnutrition in Hospitalized Patients with Gastric Cancer.
- Comprehensive Analysis of Ferroptosis-Related Markers for the Clinical and Biological Value in Gastric Cancer.
- Collective dynamics of gastric cancer cells in fluid.
- The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer.
Chinese-language papers (not in the count)14
- [Current status and prospects of minimally invasive surgical treatment for gastric cancer].
- [Strategies for supra-pancreatic lymph node dissection in laparoscopic gastric cancer surgery].
- [Clinical application of intraperitoneal chemotherapy ports in patients with gastric cancer and peritoneal metastases].
- [Clinical value and implementation strategies of normothermic intraperitoneal and systemic chemotherapy (NIPS) in the treatment of gastric cancer with peritoneal metastasis].
- [Key measures to improve the efficacy of diagnosis and treatment of gastric cancer with peritoneal metastasis].
- [Analysis of discordant results between multiplex fluorescence PCR-capillary electrophoresis for microsatellite instability (MSI) detection and immunohistochemistry (IHC) for mismatch repair (MMR) protein expression in gastrointestinal aden
- [Clinical significance of combined therapy with immune checkpoint inhibitor in perioperative treatment for locally advanced gastric cancer or adenocarcinoma of gastroesophageal junction].
- [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
- [Preliminary analysis of the promotion effect of laparoscopic standardized surgical treatment for gastric cancer in regional medical centers in Shanghai].
- [Small steps to thousands of miles: a tribute to Chinese laparoscopic gastric cancer surgery].
- [Digestive tract reconstruction after laparoscopic proximal gastrectomy for adenocarcinoma of esophagogastric junction].
- [Strategies of chemotherapy for peritoneal metastasis of gastrointestinal cancer].
- [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
- [Current status and prospect of perioperative therapy for locally advanced gastric cancer].
All its trials on ClinicalTrials.gov, any status58
- GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
- Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
- Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
- IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
- Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
- Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
- The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
- Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
- Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
- Effect of a Self-designed MET Exercise Intervention on Cancer-related Fatigue in Patients With Gastric Cancer
- Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
- Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
- Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
- Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
- In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors
- Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
- ctDNA Screening in Advanced HER2 Positive Gastric Cancer
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
- Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
- mFLOT Chemotherapy as First-line Treatment in GC
- Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
- Escorting Octogenarian for Gastric Cancer Surgery
- Early Detection of Postoperative Anastomotic Leak by CT
- Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
- Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
- A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Performing Laparoscopic Surgery for Colorectal and Gastric Cancer Outside the Primary Registered Medical Institution
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
Cancer
Osteosarcoma
骨肉瘤Led 13 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.
- Open trials as a site
- 0
- led by another institution
60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT06114225
Age 10 years to 65 years (registered criteria)
Led by Ruijin HospitalShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led13
- Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma.
- Chemotherapeutic drug-triggered AEP-cleaved G3BP1 orchestrates stress granules/nucleoli/mitochondria in osteosarcoma.
- Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis.
- Spectral computed tomography-guided radiotherapy of osteosarcoma utilizing BiOI nanosheets.
- Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
- Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
- Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma.
- Superenhancers activate the autophagy-related genes Beclin1 and LC3B to drive metastasis and drug resistance in osteosarcoma.
- DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment.
- Current Status and Prospects of Clinical Treatment of Osteosarcoma.
- Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma.
- Development and analysis of long non-coding RNA-associated competing endogenous RNA network for osteosarcoma metastasis.
- Peritumoral Microgel Reservoir for Long-Term Light-Controlled Triple-Synergistic Treatment of Osteosarcoma with Single Ultra-Low Dose.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)15
- MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
- Isolation of extracellular vesicle with different precipitation-based methods exerts a tremendous impact on the biomarker analysis for clinical plasma samples.
- Establishment of a dynamic osteosarcoma biobank: Ruijin experience.
- Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
- Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma.
- ASO Author Reflections: Metastatic Biopsy of Osteosarcoma with Circulating RNA.
- Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.
- Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.
- Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth.
- Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.
- Primary, cardiac, fibroblastic osteosarcoma: A case report.
- Patellar height influences knee function in patients with aggressive bone tumors of the proximal tibia after endoprosthetic reconstruction.
- Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.
- Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT.
- Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis.
All its trials on ClinicalTrials.gov, any status5
- Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
- Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma
- Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
- Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- [Analysis and comparison of the clinical features and prognosis between extra - gastrointestinal stromal tumors and duodenal gastrointestinal stromal tumors].
- [Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].
- Identifying therapeutic targets in gastric cancer: the current status and future direction.
- Facilitating retroflexed endoscopic full-thickness resection through loop-mediated or rope-mediated countertraction (with videos).
- Comparison of the post-operative outcomes and survival of laparoscopic versus open resections for gastric gastrointestinal stromal tumors: A multi-center prospective cohort study.
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 22 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.3%.
- Open trials led
- 0
- recruiting or about to
16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPhase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07914556
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- Early phase 1
- Started
- 2025-12
- Registry
- NCT07294625
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou
- RecruitingA Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Phase
- Phase 1
- Started
- 2023-03
- Registry
- NCT05759793
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Phase
- Phase 4
- Started
- 2022-03
- Registry
- NCT05201781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
- Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma.
- Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.
- Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.
- Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.
- Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
- Challenges facing CAR T-cell immunotherapy in multiple myeloma.
- Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma.
- Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.
- Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.
- Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma.
- Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
- PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
- Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.
- Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.
- Integrative analysis of an endoplasmic reticulum stress-related signature in multiple myeloma.
- Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.
- Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
- Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
- SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.
- Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
Chinese-language papers (not in the count)7
- [Characteristics and Risk Analysis of COVID-19 Infection in Patients with Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation].
- [Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era].
- [Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma].
- [Research progress in targeting GPRC5D for the treatment of multiple myeloma].
- [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
- [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
- [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
All its trials on ClinicalTrials.gov, any status23
- Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
- Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of Daratumumab
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 11 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 4.9%.
9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07838714
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingInaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06718244
Age 16 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEx Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07087847
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingBEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07301138
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingClinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06641024
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Resolving Leukemia Heterogeneity and Lineage Aberrations with HematoMap.
- Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.
- Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α.
- BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review.
- Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.
- Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia.
- Transcription factor 12-mediated self-feedback regulatory mechanism is required in DUX4 fusion leukaemia.
- Transcription factor abnormalities in B-ALL leukemogenesis and treatment.
- Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.
- Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.
- Purification, crystallization, and X-ray diffraction analysis of myocyte enhancer factor 2D and DNA complex.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status8
- Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
- A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
- A Multi-center Retrospective Study of INO Treating B-ALL
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
- To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)5
- POS0387 NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATE CYTOKINE STORM IN AUTOIMMUNE AND AUTOINFLAMMATORY DISEASE BY PROMOTING STING-MEDIATED MYELOPOIEIS
- POS1430 GENETIC LANDSCAPE OF ADULT-ONSET STILL'S DISEASE WITH MACROPHAGE ACTIVATION SYNDROME: IDENTIFYING KEY RISK LOCI FOR DISEASE MECHANISMS AND PERSONALIZED TREATMENT
- Ruxolitinib concentrations in cerebrospinal fluid in patients with hemophagocytic lymphohistiocytosis and potential significance of central nervous system involvement
- The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis
- Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Shanghai for beta thalassaemia157 hospitals in China for beta thalassaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Recruitingβ-Thalassemia Treatment With KL003 Cell Injection
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Registry
- NCT06280378
Age 3 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin
- RecruitingA Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- Phase
- Phase 1
- Started
- 2024-01
- Registry
- NCT06465550
Age 3 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status5
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- β-Thalassemia Treatment With KL003 Cell Injection
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
- Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
Blood disorders
Haemophilia A
血友病 ALed 5 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.
- Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms.
- Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.
- Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.
- Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)11
- Maternal microchimerism protects hemophilia A patients from inhibitor development.
- In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A.
- [A case of acquired hemophilia A with multiple superficial blistering skin disorders as the main manifestation].
- [Optimized AAV package and experimental application of recombinant AAV8/hFⅧ for gene therapy on hemophilia A mice].
- Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII.
- Inhibitor eradication and bleeding management of acquired hemophilia A: a single center experience in China.
- Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.
- Spectrum and origin of mutations in sporadic cases of haemophilia A in China.
- Complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis.
- AccuCopy quantification combined with pre-amplification of long-distance PCR for fast analysis of intron 22 inversion in haemophilia A.
- Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.
All its trials on ClinicalTrials.gov, any status8
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- China ADVATE PTP Study
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shanghai for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Moyamoya disease
烟雾病Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status8
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 2 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 4.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Shanghai for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Fabry disease
法布雷病Led 3 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 4.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease
No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.
- Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients.
- Quantitative evaluation of retinal and choroidal changes in Fabry disease using optical coherence tomography angiography.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status2
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
IgA nephropathy
IgA 肾病Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.
26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of Telitacicept in IgAN
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06654596
Age 18 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingThe Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT04858724
Age not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of SHR-2173 in Participants With Primary IgA Nephropathy
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07354932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Thickening of Glomerular Basement Membrane Is Associated with Long-Term Prognosis in Patients with IgA Nephropathy.
- Uncovering Rare Coding Variants in IgA Nephropathy.
- Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.
- A Validation Study Comparing Risk Prediction Models of IgA Nephropathy.
Earlier papers (2016–2020)9
- A Rare Genetic Defect of MBL2 Increased the Risk for Progression of IgA Nephropathy.
- Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.
- IgA Nephropathy Susceptibility Loci and Disease Progression.
- A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
- [The clinicopathological characteristics of diabetic nephropathy and non-diabetic renal diseases in diabetic patients].
- Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.
- Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese.
- Bilateral Posterior Scleritis Presenting as the First Manifestation of Immunoglobulin A Nephropathy: Case Report and Review of the Literature.
- Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.
All its trials on ClinicalTrials.gov, any status13
- Efficacy and Safety of Telitacicept in IgAN
- The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
- Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
- Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
- Bortezomib for Treating Glomerular Diseases
- Rituximab and RASi in Patients with IgAN
- A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
- A Study of SHR-2173 in Participants With Primary IgA Nephropathy
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Getting in touch
Name card to show staff or a driver
上海交通大学医学院附属瑞金医院
Ruijin Hospital
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.